← Alle Unternehmen
Über das Unternehmen
Gene therapy is changing the future of medicine, receiving the first FDA approval for eye disease in 2017. Adeno-associated virus (AAV) is the most efficient vector for delivering genes to the eye. However, it displays relevant drawbacks/limits that may render the treatment ineffective. EVIS Bioscience developed a next-generation non-viral vehicle for safe gene delivery into the retina. Founded by Dr Elita Montanari, Prof. Gianfranco Vento, and Tommaso Caselli, EVIS Bioscience spun out of ETH Zürich in June 2024. The company's technology enables the efficient loading of genes into natural extracellular vesicles (EVs), which may target specific tissues. With the rise of novel genetic therapies, the market for delivery technologies has surged and is projected to reach $12 billion by 2030.